AbbVie Q2 2026: Skyrizi and Rinvoq Drive a Double Beat

As seen on the 24/7 Wall St. homepage on July 31, 2026.

ABBV AbbVie Inc.
Q2 2026
EPS
$3.65
est $3.61 +1.2%
Revenue
$16.99B
est $16.76B +1.4%

Skyrizi and Rinvoq both cracked 24% growth to power a clean double beat, proving AbbVie's post-Humira franchise can absorb a $10.9 billion acquisition and still deliver operational outperformance.

Continue ReadingShow less

AbbVie reported Q2 2026 adjusted EPS of $3.65, edging past the consensus estimate of roughly $3.61 and extending a run of beats that stretches back through every quarter shown in recent history save Q1 2026, when the company came in just a hair under expectations. Revenue landed at $16.99 billion against an estimate of $16.76 billion, a beat of about 1.4%. Together, the two figures represent a clean double beat — stronger on the top line than on the bottom.

The headline story inside the results is the continued momentum of Skyrizi and Rinvoq, both of which cracked 24% growth in the quarter. That pace matters because it speaks directly to AbbVie's ability to replace the revenue that Humira has been shedding to biosimilar competition — a transition that has weighed on the investment thesis for years. Both drugs treat immunological conditions across multiple indications, giving them a broader addressable market than a single-disease franchise would carry.

Sponsored

Are You Ready To Retire, Or Years Behind?

Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.

The quarter also arrives in the context of AbbVie having absorbed a $10.9 billion acquisition, making the operational outperformance more notable than the headline numbers alone suggest. Investors will be watching whether Skyrizi and Rinvoq can sustain growth at this rate as they scale, and whether the acquired business begins contributing meaningfully to results in coming quarters.

Sources

Mentioned: ABBV

Related Market Updates

52-week highs
6 stocks hit new 52-week highs this week
  • SSentinelOne$20.94+6.1%
  • KOCoca-Cola$91.1+2.3%
  • EXPEExpedia$321.63+1.3%
  • ABNBAirbnb$187.3+1.2%
  • ABBVAbbVie$264.96+1.0%
  • PFEPfizer$28.07+0.6%

Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.

Read more
ABBV AbbVie
New 52-week high $265.97 +1.0% vs prior high · 2026-07-29
$271$233$196

AbbVie touched a new 52-week high at $265.97, clearing its July 29 peak. The $470 billion pharma has left its spring range near $200 behind.

Read more
52-week highs
9 stocks hit new 52-week highs this week
  • SNOWSnowflake$293.28+6.4%
  • GMGeneral Motors$88.86+5.0%
  • KOCoca-Cola$87.59+4.9%
  • ABNBAirbnb$151.52+2.8%
  • BRKRBruker$62.84+2.6%
  • AAPLApple$308.91+1.9%
  • EXPEExpedia$294.74+1.4%
  • ABBVAbbVie$250.94+0.8%
  • NETCloudflare$278.98+0.6%

Nine market leaders hit 52-week highs this week, from Snowflake up 6.4% above its prior peak to Cloudflare edging out gains. Breadth across tech, consumer staples, and auto signals conviction above the tape.

Read more
ABBV AbbVie
New 52-week high $263.2 +0.8% vs prior high · 2026-07-02
$270$224$178

AbbVie hits a fresh 52-week peak of $263.20, capping a sharp rally that's lifted the stock nearly 43% from January lows.

Read more
ABBV AbbVie
Dividend raised $1.73 ex-date 2026-07-15 · 2.80% yield · 13 yrs paying · +5.5% YoY

AbbVie hiked its dividend 5.5% to $1.73 per share, extending a 13-year streak of unbroken payouts even as biosimilar pressure weighs on Humira's top-line growth.

Read more